Eli Lilly strikes $2.75 billion deal with Hong Kong's Insilico Medicine to commercialize AI-discovered drugs globally; $115 million upfront payment with milestone-based payouts for biotech partnership expanding since 2023.

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025.Mike Blake | ReutersBEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.The agreement will give Insilico $115 million up front, with the remainder subject to regulatory and commercial milestones, along with royalties on future sales, according to the compani...